

Dual MC3R/MC4R Activation Drives Weight Loss, Limits Rebound, and Preserves Lean Mass in Obese Nonhuman Primates

ENDO 2026

Dr. Jillian L Seiler, PhD



Endevica **Bio**



Opportunities Beyond GLP-1 Therapies

The Potential of Melanocortin Agonists



Current therapies have transformed care,
but unmet needs remain

~15%

Non-responders to
treatment²

1.5 years

Avg time to return to baseline weight
after treatment cessation⁴


~70%

People who stop therapy within 2
years; 28% due to side effects³

20-50%



Fraction of total weight loss made up of
lean mass, including skeletal muscle¹

**Melanocortin activation may drive
healthier, more durable weight loss⁵**



The melanocortin pathway is a validated regulator of appetite and metabolism

Melanocortin System





Previous melanocortin efforts have focused primarily on MC4R

The melanocortin pathway is a validated regulator of appetite and metabolism



Melanocortin System




The endogenous system engages both MC3R and MC4R


Selective melanocortin agonists

a chemistry breakthrough to answer biological questions

MC3R selective



MC4R selective





● MC3R
■ MC4R

MC3R and MC4R:

What roles do they play in an acute challenge to homeostasis?


Food Intake Response after Overnight Fast



Do these roles change under a chronic homeostatic challenge?



Obese NHPs, high-fat diet
Chronic dose administration




MC4R agonism drives weight loss



MC3R agonism preserves lean mass



Our lead clinical obesity candidate: EBMC-710GO



Orally deliverable



CNS-penetrant




Plasma stable




No GI side effects

Oral 710GO Promotes Weight Loss in Obese NHPs




710GO promotes healthier weight loss in DIO NHPs


Minimal rebound post-treatment



Preferentially targets fat mass



710GO combines with semaglutide for increased weight loss in obese NHPs



710GO offers a differentiated way to achieve a healthier weight loss profile

MC3R's Unique Contributions

Acute fast



Role:
control refeeding
response


Chronic obesity



Role:
energy
partitioning

Dual MC Agonism is Key

Melanocortin-driven
weight loss



710GO's Critical Advantages

ORAL



GI SAFE



DURABLE



LEAN



Thank You!



Chemistry Team

- Jordan Delev, Head of R&D
- Dr. Anna Impastato
- Kade Kelley
- Dr. Claudia Prindle
- Thomas Bennett
- Dr. Benjamin Rajewski
- Dr. Andres Arango
- Dr. Sanjay Kumar

Executive Team

- Russell Potterfield, CEO
- Dr. Daniel Marks, CM&SO

Biology Team

- Dr. Emma Zhang
- Dr. Bradley Studnitzer
- Dr. Jillian Seiler

Clinical Development Team

- Dr. Barry Badeau
- Dr. Wilmon Grant
- Dr. William Riedl
- Dr. Meghan Joly
- Dr. Allison Gardner

Contact me at jillian@endevicabio.com